The changing face of venous thromboembolism management in England
Sreeram V Ramagopalan, Robert Carroll, Maria Ulvestad, Faisal Mehmud and Raza Alikhan discuss the assessment of physician comfort in treating patients with venous thromboembolism in this short communication.
The term venous thromboembolism (VTE) encompasses the presence of pulmonary embolism (PE) and/or deep vein thrombosis (DVT). It is estimated that VTE affects over 10 million people worldwide annually. Oral vitamin K anticoagulation therapy (VKA) is the mainstay of treatment for VTE patients, although non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as viable alternatives to VKA therapy in patients with VTE.
In this short communication, published in Future Cardiology, researchers from Bristol-Myers Squibb (UK) and University Hospital Wales (Cardiff, UK) conducted an observational, retrospective cohort study that evaluated VTE treatment in England using the Clinical Practice Research Datalink (CPRD) linked to Hospital Episode Statistics (HES) data.